Samarth Kulkarni Sells 19,582 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at $12,468,589.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Samarth Kulkarni also recently made the following trade(s):

• On Friday, March 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $72.48, for a total value of $1,449,600.00.
• On Monday, March 11th, Samarth Kulkarni sold 9,802 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $78.26, for a total value of $767,104.52.
• On Tuesday, February 20th, Samarth Kulkarni sold 6,370 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $79.67, for a total value of $507,497.90.
• On Thursday, February 15th, Samarth Kulkarni sold 20,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $80.36, for a total value of $1,607,200.00.
• On Monday, January 29th, Samarth Kulkarni sold 50,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.51, for a total value of $3,025,500.00.

CRISPR Therapeutics Trading Up 1.1 %

Shares of CRSP opened at $56.16 on Friday. The business’s 50-day moving average price is $73.51 and its 200 day moving average price is $63.34. The stock has a market capitalization of $4.77 billion, a P/E ratio of -28.65 and a beta of 1.76. CRISPR Therapeutics AG has a 1-year low of $37.55 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to analysts’ expectations of $148.72 million. The company’s revenue for the quarter was up 3253.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.41) EPS. On average, research analysts predict that CRISPR Therapeutics AG will post -6.24 earnings per share for the current year.

Hedge Funds Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. CWM LLC grew its stake in CRISPR Therapeutics by 80.7% during the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after acquiring an additional 260 shares in the last quarter. Tradewinds Capital Management LLC grew its stake in CRISPR Therapeutics by 545.5% during the 3rd quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock valued at $32,000 after acquiring an additional 600 shares in the last quarter. Blue Trust Inc. purchased a new position in CRISPR Therapeutics during the 4th quarter valued at about $32,000. Headlands Technologies LLC purchased a new position in CRISPR Therapeutics during the 3rd quarter valued at about $34,000. Finally, Bourgeon Capital Management LLC grew its stake in CRISPR Therapeutics by 1,000.0% during the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after acquiring an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

CRSP has been the topic of a number of research analyst reports. Chardan Capital raised their price target on CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Needham & Company LLC reissued a “buy” rating and set a $90.00 price target on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Morgan Stanley raised their price target on CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a report on Monday, February 26th. Wolfe Research began coverage on CRISPR Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating on the stock. Finally, Royal Bank of Canada raised their target price on CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research note on Thursday, February 22nd. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $76.29.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.